CN101095933A - Chinese traditional medicine compound recipe for healing bones and treating wound - Google Patents
Chinese traditional medicine compound recipe for healing bones and treating wound Download PDFInfo
- Publication number
- CN101095933A CN101095933A CNA2007100434439A CN200710043443A CN101095933A CN 101095933 A CN101095933 A CN 101095933A CN A2007100434439 A CNA2007100434439 A CN A2007100434439A CN 200710043443 A CN200710043443 A CN 200710043443A CN 101095933 A CN101095933 A CN 101095933A
- Authority
- CN
- China
- Prior art keywords
- group
- radix
- compound recipe
- fracture
- medicine compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a Chinese compound medicament for treating bone fracture, which is prepared from the raw materials of dipsacus root, drynaria, native copper, glutinous rehmannia, Chinese angelica root, ground beetle, root of herbaceous peony, licorice root, fresh ginger and deglued antler powder by a weight ratio of 1 : 0.5-2 : 0.38-1.5 : 0.5-2 : 0.38-1.5 : 0.25-1 : 0.5-2 : 0.13-0.5 : 0.25-1 : 0.25-1.
Description
Technical field
The present invention relates to a kind of Chinese medicine compound of recipe for healing bones and treating wound, fracture, osteomiosis, bone splits that treatment wound etc. causes, cervical spondylosis and joint, the caused swelling of soft tissue sprain, pain belong to technical field of Chinese medicines.
Background technology
Union of fracture is a complexity and repair process biology of high-sequential needs several months even the time more than 1 year to heal, and the patient can not orthobiosis and work during this period.And this process is subjected to the influence and the adjusting of whole body and local many factors, the fracture of about 5%-10% is because a variety of causes generation delayed union or disunion, thereby need surgical intervention, bring huge misery and burden, and often cause the later stage function relatively poor to the patient.How to promote union of fracture, shorten the union of fracture cycle, improve healing quality is the hot issue of orthopaedics research field always.The fixed non-operative treatment of many employings during the western medical treatment fracture, though higher cure rate is arranged, the time of external fixation is longer, often causes suffering from limb the useless sexual dysfunction of using takes place.Chinese medicine just is used to treatment of fractures since ancient times, promotes this problem of union of fracture to carry out more clinical trial around Chinese medicine.Be method with blood circulation promoting and blood stasis dispelling, promoting the circulation of QI for relieving swelling pain relieving during the Chinese traditional treatment fracture initial stage; Treatment is fractured mid-term based on reunion of bone, promoting regeneration of tissue by regulating nutrient QI; Fracture and then need strengthening bone and muscle, invigorating the liver and kidney, qi and blood invigorating late period.Document Investigation finds that Chinese patent CN1387905A has announced a kind of Orally taken fracture setting Chinese medicine, and its prescription is a main purpose with blood circulation promoting and blood stasis dispelling, reducing swelling and alleviating pain.But can find that from the angle of Chinese medicine it is early stage that this compound recipe is only applicable to fracture.
Summary of the invention
The purpose of this invention is to provide a kind of fracture, osteomiosis, the bone splits that wound etc. causes, Chinese medicine compound of a kind of recipe for healing bones and treating wound of cervical spondylosis and joint, the caused swelling of soft tissue sprain, pain for the treatment of.
For realizing above purpose, technical scheme of the present invention provides a kind of Chinese medicine compound of recipe for healing bones and treating wound, it is characterized in that the weight portion proportioning of described raw material is: Radix Dipsaci: Rhizoma Drynariae: Pyritum (calcined): Radix Rehmanniae: Radix Angelicae Sinensis: Eupolyphaga Seu Steleophaga: the Radix Paeoniae Alba: Radix Glycyrrhizae: Rhizoma Zingiberis Recens: Cornu Cervi Degelatinatum 1: 0.5-2: 0.38-1.5: 0.5-2: 0.38-1.5: 0.25-1: 0.5-2:: 0.13-0.5: 0.25-1: 0.25-1.
Radix Dipsaci invigorating the liver and kidney, reuniting the fractured tendons and bones, blood circulation regulating, can significantly promote the quantity that osteoblastic propagation, increase expression of ALP and mineralising tuberosity form, promote the expression of osteoblast Bone Gla protein and I procollagen type α mRNA, and it can significantly improve osteoblastic proliferation rate, S phase cells ratio and cell proliferation index, reduces apoptosis rate and G
0-G
1The phase cells ratio.Can effectively promote osteoblastic differentiation, propagation, prevent TNF-a Induced Apoptosis in Osteoblasts, be the promotion union of fracture, prevent and treat osteoporotic mechanism.The effect that Rhizoma Drynariae has the kidney invigorating, invigorates blood circulation, stops blooding, the Rhizoma Drynariae extracting solution has facilitation to the increment of rabbit bone marrow stromal cell, thereby promotes medullary cell to osteoblastic conversion, and Rhizoma Drynariae has the effect of into union of fracture.Pyritum (calcined) eliminating stasis to stop pain, reunion of bone; Eupolyphaga Seu Steleophaga breaks congestion, reuniting the fractured tendons and bones; Chinese angelica blood supplementing and blood, menstruction regulating and pain relieving, moisturize laxation; The yellow clearing away heat and cooling blood of Radix Rehmanniae, YIN nourishing and the production of body fluid promoting; The pain relieving of Radix Paeoniae Alba suppressing the hyperactive liver, nourishing blood for regulating menstruation, astringing YIN to stop sweating; Rhizoma Zingiberis Recens activating blood and removing stasis, reducing swelling and alleviating pain; Cornu Cervi Degelatinatum warming the kidney to activate YANG, astringing to arrest bleeding; Radix Glycyrrhizae heat-clearing and toxic substances removing, relieving spasm to stop pain, coordinating the actions of various ingredients in a prescription.The present invention is that the principal agent set a broken bone provides the pharmacology foundation with Radix Dipsaci, Rhizoma Drynariae.
The present invention selects Chinese crude drug Radix Dipsaci, Rhizoma Drynariae, Pyritum (calcined), Eupolyphaga Seu Steleophaga, Radix Angelicae Sinensis, Radix Rehmanniae, the Radix Paeoniae Alba, Rhizoma Zingiberis Recens, Cornu Cervi Degelatinatum, Radix Glycyrrhizae 10 flavor Chinese prescriptions for use according to China's tradition Chinese medicine " activating blood circulation to dissipate blood stasis, reducing swelling and alleviating pain, symplectic bone wound healing, liver and kidney tonifying " principle.With Radix Dipsaci, Rhizoma Drynariae is monarch drug, invigorating the liver and kidney, reuniting the fractured tendons and bones, mediation blood vessels, invigorating kidney, promoting blood circulation.With Pyritum (calcined), Radix Rehmanniae, when being classified as ministerial drug, main row loose blood and relieving pain, removing mass collateral dredging by blood stasis, are filled out bone marrow.With Eupolyphaga Seu Steleophaga, the Radix Paeoniae Alba, Cornu Cervi Degelatinatum, Rhizoma Zingiberis Recens is adjuvant drug, leads the effect of the capable yin fluid astringing that nourishes blood, easing the affected liver to relieve pain, activating blood and removing stasis, reducing swelling and alleviating pain, granulation promoting treatment scar.With the Radix Glycyrrhizae is messenger drug, hard muscles and bones, longue meat.Main Radix Dipsaci, the Rhizoma Drynariae used of the present invention is with invigorating the liver and kidney, reuniting the fractured tendons and bones, add that Radix Rehmanniae, Pyritum (calcined), Radix Angelicae Sinensis bring into play the effect of activating blood circulation to dissipate blood stasis better, the symplectic bone of invigorating blood circulation that adds Eupolyphaga Seu Steleophaga, the Radix Paeoniae Alba, Cornu Cervi Degelatinatum, Rhizoma Zingiberis Recens again strengthens to be renderd a service, be aided with the Radix Glycyrrhizae coordinating the actions of various ingredients in a prescription, reach invigorating the liver and kidney jointly, the effect of mediation blood vessels, reuniting the fractured tendons and bones.
Advantage of the present invention is to treat fracture, osteomiosis, the bone splits that wound etc. causes, cervical spondylosis and joint, the caused swelling of soft tissue sprain, pain are applicable to that not only fracture is early stage, also are applicable to treatment fracture mid-term and late period simultaneously.
The specific embodiment
The invention will be further described below in conjunction with embodiment.
Embodiment 1
Described ingredients weight parts proportioning is:
Radix Dipsaci 6g, Rhizoma Drynariae 6g, Pyritum (calcined) 4.5g, Radix Rehmanniae 6g, Radix Angelicae Sinensis 4.5g, Eupolyphaga Seu Steleophaga 3g, Radix Paeoniae Alba 6g, Radix Glycyrrhizae 1.5g, Rhizoma Zingiberis Recens 3g, Cornu Cervi Degelatinatum 3g.
Embodiment 2
Radix Dipsaci 12g, Rhizoma Drynariae 12g, Pyritum (calcined) 9g, Radix Rehmanniae 12g, Radix Angelicae Sinensis 9g, Eupolyphaga Seu Steleophaga 6g, Radix Paeoniae Alba 12g, Radix Glycyrrhizae 3g, Rhizoma Zingiberis Recens 6g, Cornu Cervi Degelatinatum 6g.
Embodiment 3
Radix Dipsaci 24g, Rhizoma Drynariae 24g, Pyritum (calcined) 18g, Radix Rehmanniae 24g, Radix Angelicae Sinensis 18g, Eupolyphaga Seu Steleophaga 12g, Radix Paeoniae Alba 24g, Radix Glycyrrhizae 6g, Rhizoma Zingiberis Recens 12g, Cornu Cervi Degelatinatum 12g.
The present invention's preparation method routinely makes pharmaceutically said oral formulations, comprises decoction, electuary, powder, capsule, tablet, syrup and suspensoid.
The preparation method of above-mentioned each component is: with medical material, Pyritum is decocted first behind 1h, the Eupolyphaga Seu Steleophaga down, and decocting boils 3 times, each 1h.Merge extractive liquid, filters, and concentrating under reduced pressure gets fluid extract, disperses to make extractum more than back 60 ℃ of drying under reduced pressure 12h, pulverizes, and mix homogeneously is granulated, oven dry.
The present invention's preparation method routinely makes pharmaceutically said oral formulations, comprises decoction, electuary, powder, capsule, tablet, syrup and suspensoid.
Carried out the animal pharmacodynamics test by specific embodiment 2 prepared preparations, confirmed that it has the effect of good " activating blood circulation to dissipate blood stasis, symplectic bone wound healing, reducing swelling and alleviating pain ".
1. promote the union of fracture experiment
30 of rabbit are provided by INM, body weight 1.8-2.2kg, and the male and female dual-purpose, single cage is raised.3% pentobarbital 1mlkg
-1Intravenous anesthesia, aseptic condition operation down separate the two forelimb radius of rabbit, cause hypomere incomplete fracture in the bilateral radius with double-deck hacksaw, the wide about 3mm of fracture, and the degree of depth is 1/2 of a radius diameter.Skin suture, intramuscular injection gentamycin 40,000 unit infection.The postoperative animal is divided into 5 groups by body weight and sex, is respectively matched group (distilled water), basic, normal, high dosage group of compound recipe (1: 3: 6, low dose group is equivalent to the clinical treatment amount) and positive controls.Back 2d begins gastric infusion.Get radius after 20 days and carry out the observation of X sheet.X sheet appraisal result shows that compound recipe high dose group and positive group relatively have significant difference with the blank group, point out its compound recipe of the present invention can promote union of fracture.(P＜0.05)。
The two radius X sheet scoring statistics of table 1 experimental rabbit (n=5-6)
| Dosage group high dose group in the positive group of the blank group low dose group | Postoperative 20d | The P value | |||
| + 3 3 2 | ++ 1 2 1 1 1 | +++ 1 3 1 1 3 | ++++ 1 1 1 1 | - ＜0.05 ＞0.05 ＞0.05 ＜0.05 | |
2. antiinflammatory experiment
2.1 influence to the mouse peritoneal capillary permeability
The mice of 18-22g body weight, male and female half and half are divided into 5 groups by body weight and sex, are respectively matched group (distilled water), basic, normal, high dosage group of compound recipe (1: 3: 6, low dose group is equivalent to the clinical treatment amount) and aspirin group.Successive administration 7 days, 1 hour azovan blue solution (10mlkg after the last administration through tail vein injection 0.5%
-1), the glacial acetic acid solution of lumbar injection 0.6% then, every 0.2ml.After half an hour, mice is put to death.After the 5ml normal saline injected mouse peritoneal and gently rub 1min, extract whole cleaning mixture test tube of packing into, in the centrifugal 10min of 3000r/min, supernatant is in 590nm place mensuration absorbance.The compound recipe high dose group can suppress the capillary permeability increase that acetic acid causes significantly, and suppression ratio is 28.7%.
Table 2 compound recipe to the influence of mouse peritoneal capillary permeability (
N=10)
| Group | Absorbance | Suppression ratio (%) |
| Dosage group high dose group in the dosage group in the blank group aspirin group low dose group | 547.67±135.63 256.40±156.12 ** 476.20±122.07 463.83±81.74 463.83±81.74 390.50±62.18 ** | 53.2 13.0 15.3 15.3 28.7 |
Annotate: the t check,
*With the blank group than P＜0.01
2.2 xylol causes the influence of mice ear
Mice continuous irrigation stomach 7 days (grouping and dosage are with 2.1), 1h after the last administration evenly is applied to 30 μ l dimethylbenzene inside and outside the auris dextra exterior feature of mice, causes scorching back 30min, puts to death mice.Lay auricle with diameter 8mm card punch in the same area of mice left and right sides auricle, analytical balance is weighed, with about two auricle weight differences as the swelling degree.The middle dosage group of compound recipe is compared with the blank group, and there were significant differences for the swelling degree, and its suppression ratio reaches 53.2%.Table 3 compound recipe xylol cause mice ear influence (
N=10)
| Group | Swelling degree (mg) | Suppression ratio (%) |
| Blank group aspirin group low dose group | 1.95±0.81 0.69±0.47 ** 1.80±0.49 | - 64.0 7.4 |
| Middle dosage group high dose group | 0.91±0.41 ** 1.36±0.57 | 53.2 30.0 |
Annotate: the t check,
*With the blank group than P＜0.01
2.3 on Carrageenan causes the influence of rat paw edema
The rat of 160-180g body weight, male and female half and half are divided into 5 groups by body weight and sex, are respectively matched group (distilled water), basic, normal, high dosage group of compound recipe (1: 3: 6, low dose group is equivalent to the clinical treatment amount) and aspirin group.Around the rat right hind leg ankle joint, make a labelling with marking pen before the continuous irrigation stomach 7 days, last administration, with the right back sufficient volume of every rat of Instrument measuring.1h after the last administration, every right back whole plantar subcutaneous injection 1% carrageenin 0.1ml of rat causes inflammation, measures right back sufficient volume at 1h, 2h, 3h and 4h respectively, and the difference of sufficient sole of the foot volume is the swelling degree before and after the administration.Compound recipe 1h after causing inflammation can suppress the rat paw edema that carrageenin causes significantly.
Table 4 compound recipe on Carrageenan cause rat paw edema influence (
N=10)
| Group | The administration front volume | Swelling degree (ml) | |||
| 1h | 2h | 3h | 4h | ||
| Dosage group high dose group in the blank group aspirin low dose group | 1.67±0.25 1.68±0.18 1.69±0.26 1.71±0.34 1.85±0.34 | 0.31±0.17 0.14±0.09 *0.17±0.11 *0.17±0.13 *0.15±0.13 * | 0.45±0.27 0.23±0.15 *0.48±0.20 0.32±0.20 0.38±0.20 | 0.53±0.29 0.32±0.17 * 0.62±0.20 0.48±0.24 0.53±0.44 | 0.50±0.22 0.26±0.18 * 0.51±0.22 0.31±0.23 0.40±0.36 |
Annotate: the t check,
*With the blank group than P＜0.05
3. analgesic experiment
3.1 Dichlorodiphenyl Acetate causes the influence of mouse writhing reaction
Mice continuous irrigation stomach 7 days (grouping and dosage are with 2.1), behind the last administration 1h, 0.8% acetic acid 0.1ml/10g of the fresh configuration of lumbar injection, that observes mice in the 15min turns round the body number of times.Compound recipe has significant analgesic activity, and wherein the analgesic effect of middle dosage group is higher than low dose group and high dose group, and the analgesia rate reaches 49.18%.
Table 5 compound recipe Dichlorodiphenyl Acetate cause mouse writhing reaction influence (
N=10)
| Group | Turn round the body number of times among the 15min | Analgesia rate (%) |
| Dosage group high dose group in the blank group aspirin group low dose group | 47.67±11.37 10.00±6.93 ** 37.75±6.86 * 24.22±6.92 ** 32.8±8.40 ** | 79.02 20.80 49.18 31.19 |
Annotate: the t check,
*With the blank group than P＜0.05,
*With the blank group than P＜0.01
4. to the influence of rat blood rheology
The rat of 160-180g body weight, male and female half and half are divided into 5 groups by body weight and sex, are respectively matched group (distilled water), basic, normal, high dosage group of compound recipe (1: 3: 6, low dose group is equivalent to the clinical treatment amount) and aspirin group.Continuous irrigation stomach 7 days, abdominal aortic blood 3ml after the last administration puts into the centrifuge tube that the 0.5ml heparin injection is housed, gently mixing.Getting the 1ml whole blood measures.The result is as shown in table 6, compares with the blank group, and the dosage group can significantly reduce the viscosity of whole blood in the compound recipe.
Table 6 compound recipe to the influence of rat blood rheology (
N=10)
| Group | Dosage (gkg -1) | Low cutting | In cut | Height is cut |
| Dosage group high dose group in the blank group aspirin group low dose group | - 0.2 0.25 0.75 1.50. | 16.82±2.57 12.84±2.10 ** 14.36±2.64 12.61±2.30 ** 14.80±3.93 | 7.75±0.78 6.45±0.71 ** 7.08±1.04 6.76±0.89 * 7.44±1.30 | 5.92±0.53 5.05±0.46 ** 5.44±0.65 5.51±0.62 5.91±0.87 |
Annotate: the t check,
*With the blank group than P＜0.05,
*With the blank group than P＜0.01
Above-mentioned result of study shows, compound recipe can suppress mice because the capillary permeability that lumbar injection acetic acid causes increases, can reduce the mice ear that dimethylbenzene causes, the rat paw edema that carrageenin causes, can reduce mice because lumbar injection acetic acid causes the number of times of turning round body, can reduce the whole blood viscosity of rat, this results suggest compound recipe has the effect of " activating blood circulation to dissipate blood stasis, symplectic bone wound healing, reducing swelling and alleviating pain ".
47 routine tibia fibula closed fracture patients are adopted closed reduction, intramedullary nail with lock internal fixation operation, and postoperative selects 25 examples to organize as treatment at random, oral administered compound, and 22 examples are not taken medicine and are organized in contrast in addition, and the result is as follows:
The clinical union of bone time:
The treatment group clinical union of bone time is 8.6 ± 0.73 months, and matched group 11.7 ± 0.85 months through check difference significance (P＜0.05), sees Table 8.
Table 8 treatment group and matched group clinical union of bone time (moon) (
)
| Group | The example number | Healing time |
| Treatment group matched group | 25 22 | 8.6±0.75 11.7±0.85 |
Annotate: compare P＜0.05 with matched group
X-ray film inspection grading:
Postoperative 1 month, treatment group 15 examples are I level callus, matched group 6 examples; Postoperative two months, treatment group 11 examples are II level callus, matched group 5 examples; Postoperative 3 months, treatment are organized 14 examples and are reached III level callus, and matched group is 5 examples only.
Hinder the footpath variation of limb week:
Table 9 postoperative different time hinder limb Zhou Jing variation (%,
)
| The group example | The example number | Post burn (week) | |||
| 1 | 2 | 3 | 4 | ||
| Treatment group matched group | 25 22 | 92.6±0.87 93.5±0.92 | 86.1±1.21 91.2±1.35 | 74.7±0.95 88.5±1.39 | 73.4±0.44 87.5±0.69 |
Annotate: compare P＜0.05 with matched group
Originally studies show that compound recipe is used for the early treatment of closed fracture, can alleviate tissue edema, hemorrhage effectively, microcirculation improvement reduces local soft tissue tension force, plays the effect of reducing swelling and alleviating pain.Be expert at behind closed reduction, the intramedullary nail with lock internal fixation for the closed fracture case, use the curative effect that this medical instrument has more definite promotion union of fracture.
Claims (2)
1. the Chinese medicine compound of a recipe for healing bones and treating wound, it is characterized in that the weight portion proportioning of described raw material is: Radix Dipsaci: Rhizoma Drynariae: Pyritum (calcined): Radix Rehmanniae: Radix Angelicae Sinensis: Eupolyphaga Seu Steleophaga: the Radix Paeoniae Alba: Radix Glycyrrhizae: Rhizoma Zingiberis Recens: Cornu Cervi Degelatinatum is 1: 0.5-2: 0.38-1.5: 0.5-2: 0.38-1.5: 0.25-1: 0.5-2:: 0.13-0.5: 0.25-1: 0.25-1.
2. according to the Chinese medicine compound of claim 1 described a kind of recipe for healing bones and treating wound, it is characterized in that, is pharmaceutically said oral formulations, comprises decoction, electuary, powder, capsule, tablet, syrup and suspensoid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007100434439A CN101095933B (en) | 2007-07-05 | 2007-07-05 | Chinese traditional medicine compound recipe for healing bones and treating wound |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007100434439A CN101095933B (en) | 2007-07-05 | 2007-07-05 | Chinese traditional medicine compound recipe for healing bones and treating wound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101095933A true CN101095933A (en) | 2008-01-02 |
| CN101095933B CN101095933B (en) | 2010-11-03 |
Family
ID=39010156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007100434439A Expired - Fee Related CN101095933B (en) | 2007-07-05 | 2007-07-05 | Chinese traditional medicine compound recipe for healing bones and treating wound |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101095933B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102258621A (en) * | 2011-08-24 | 2011-11-30 | 中国人民解放军第四一一医院 | Chinese medicinal compound bone healing capsules and preparation method thereof |
| CN103110762A (en) * | 2013-03-23 | 2013-05-22 | 汤玮 | Traditional Chinese medicine composition for treating old fracture |
| CN105663440A (en) * | 2016-01-28 | 2016-06-15 | 张生禄 | Oral medicine for treating symptoms occurring in middle stage of fracture and soft tissue contusion |
| CN105906497A (en) * | 2016-04-18 | 2016-08-31 | 镇江高海生物药业有限公司 | A venlafaxine hydrochloride pharmaceutical composition and biological medicine uses thereof |
| CN108815292A (en) * | 2018-07-16 | 2018-11-16 | 中国人民解放军第四医院 | A kind of Chinese medicine compound prescription of recipe for healing bones and treating wound and its preparation process of preparation |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1368064A (en) * | 2001-02-05 | 2002-09-11 | 杨孟君 | Nano medicine 'yishenbugu' for tonifying kidney and strengthening bone and its preparing process |
| CN1194731C (en) * | 2002-07-06 | 2005-03-30 | 姜子英 | Orally taken fracture setting Chinese medicine |
| CN1235623C (en) * | 2003-05-19 | 2006-01-11 | 南明森 | Naturally curing fracture setting pill |
-
2007
- 2007-07-05 CN CN2007100434439A patent/CN101095933B/en not_active Expired - Fee Related
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102258621A (en) * | 2011-08-24 | 2011-11-30 | 中国人民解放军第四一一医院 | Chinese medicinal compound bone healing capsules and preparation method thereof |
| CN103110762A (en) * | 2013-03-23 | 2013-05-22 | 汤玮 | Traditional Chinese medicine composition for treating old fracture |
| CN105663440A (en) * | 2016-01-28 | 2016-06-15 | 张生禄 | Oral medicine for treating symptoms occurring in middle stage of fracture and soft tissue contusion |
| CN105906497A (en) * | 2016-04-18 | 2016-08-31 | 镇江高海生物药业有限公司 | A venlafaxine hydrochloride pharmaceutical composition and biological medicine uses thereof |
| CN108815292A (en) * | 2018-07-16 | 2018-11-16 | 中国人民解放军第四医院 | A kind of Chinese medicine compound prescription of recipe for healing bones and treating wound and its preparation process of preparation |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101095933B (en) | 2010-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104043049A (en) | Traditional Chinese medicine composition for treating hyperplasia of mammary glands | |
| CN101095933B (en) | Chinese traditional medicine compound recipe for healing bones and treating wound | |
| CN102886033A (en) | Traditional Chinese medicine preparation for promoting postpartum recovery of parturients and shortening lochial time | |
| CN104758844A (en) | Traditional Chinese medicine for treating premature ovarian failure | |
| CN106728615A (en) | Chinese medicine composition for synthetism life bone and preparation method thereof | |
| CN103341013B (en) | A kind of Chinese medicine for the treatment of lumbago and skelalgia | |
| CN104758607A (en) | Traditional Chinese medicine composition for treating premature ovarian failure | |
| CN103285203B (en) | Traditional Chinese medicine composition for preventing and treating bone fracture and preparation method thereof | |
| CN104922363A (en) | Traditional Chinese medicine composite for treating osteoproliferation | |
| CN104857311A (en) | Traditional Chinese medicine for treating ischemic necrosis of femoral head | |
| CN101259214B (en) | Medicine for treating hyperplasia of mammary glands | |
| CN101708292B (en) | Chinese medicament for treating rheumatic and rheumatoid diseases | |
| CN103784824A (en) | Chinese herbal preparation for treating lumbar disc herniation and rheumatoid | |
| CN102836276B (en) | Bone spur softening pill for treating osteoarthritis | |
| CN102145099A (en) | Traditional Chinese medicine for treating infertility caused by liver stagnation | |
| CN101979035A (en) | Medicament for treating gynecological abnormal leucorrhea | |
| CN104547474B (en) | A kind of purposes of Chinese medicine preparation in treatment liver-cancer medicine is prepared | |
| CN104547862A (en) | Use of traditional Chinese medicine preparation in preparation of medicine for treating bone fracture | |
| CN105687659A (en) | Medicine patch for treating cesarean-postoperative abdominal incision sclerosis | |
| CN105412244A (en) | Traditional Chinese medicine composition treating gynecological cervicitis | |
| CN1287829C (en) | Shenjin pill for treating hyperplastic osteoarthritis and rheumatism and its preparing method | |
| CN104324252A (en) | Traditional Chinese medicine preparation for treating sudden dizziness | |
| CN101979010A (en) | Chinese medicament for treating metrorrhagia | |
| CN102078387A (en) | Traditional Chinese medicine for treating fibroid and ovarian cyst | |
| CN111905056A (en) | Chinese medicinal composition for treating rheumatism, rheumatoid diseases and various osteopathia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20101103 Termination date: 20170705 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |